Rapid Therapeutic Science Laboratories (Rapid Therapeutic Science Laboratories) Operating Income : $-0.55 Mil (TTM As of Jun. 2023)

View and export this data going back to 2013. Start your Free Trial

What is Rapid Therapeutic Science Laboratories Operating Income?

Rapid Therapeutic Science Laboratories's Operating Income for the three months ended in Jun. 2023 was $-0.10 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Jun. 2023 was $-0.55 Mil.

Warning Sign:

Rapid Therapeutic Science Laboratories Inc had lost money in 92% of the time over the past 12quarters.

Operating Margin % is calculated as Operating Income divided by its Revenue. Rapid Therapeutic Science Laboratories's Operating Income for the three months ended in Jun. 2023 was $-0.10 Mil. Rapid Therapeutic Science Laboratories's Revenue for the three months ended in Jun. 2023 was $0.00 Mil. Therefore, Rapid Therapeutic Science Laboratories's Operating Margin % for the quarter that ended in Jun. 2023 was %.

Rapid Therapeutic Science Laboratories's 5-Year average Growth Rate for Operating Margin % was 0.00% per year.

Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Rapid Therapeutic Science Laboratories's annualized ROC % for the quarter that ended in Jun. 2023 was -7.85%. Rapid Therapeutic Science Laboratories's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2023 was 26.75%.

Rapid Therapeutic Science Laboratories Operating Income Historical Data

The historical data trend for Rapid Therapeutic Science Laboratories's Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rapid Therapeutic Science Laboratories Operating Income Chart

Rapid Therapeutic Science Laboratories Annual Data

Trend

Mar13

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Dec21

Dec22

Operating Income

Get a 7-Day Free Trial

-0.15

-0.17

-0.43

-2.18

-1.26

Rapid Therapeutic Science Laboratories Quarterly Data
	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23
Operating Income	Get a 7-Day Free Trial															-0.13	-0.37	0.03	-0.10	-0.10

Rapid Therapeutic Science Laboratories Operating Income Calculation

Operating Income, is the profit a company earned through operations. All expenses, including cash expenses such as cost of goods sold (COGS), research & development, wages, and non-cash expenses, such as depreciation, depletion and amortization, have been deducted from the sales.

Operating Income for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.55 Mil.

Rapid Therapeutic Science Laboratories (OTCPK:RTSL) Operating Income Explanation

1. Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Rapid Therapeutic Science Laboratories's annualized ROC % for the quarter that ended in Jun. 2023 is calculated as:

	ROC % (Q: Jun. 2023 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Mar. 2023 )	+	Invested Capital (Q: Jun. 2023 ))	/ count )
=	-0.416 * ( 1 - 0% )	/	( (5.362	+	5.238)	/ 2 )
=	-0.416	/	5.3
=	-7.85 %

where

	Invested Capital		(Q: Mar. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	2.034	-	0.884	-	( 0.018	-	max(0, 4.463	-	0.251	+	0.018	))
=	5.362

	Invested Capital		(Q: Jun. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	2.074	-	0.944	-	( 0.002	-	max(0, 4.426	-	0.318	+	0.002	))
=	5.238

Note: The Operating Income data used here is four times the quarterly (Jun. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

Rapid Therapeutic Science Laboratories's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2023 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Jun. 2023 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Mar. 2023		Q: Jun. 2023
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	0.428	/	( ( (1.614 + max(-0.863, 0))	+	(1.586 + max(-0.795, 0)) )	/	2 )
=	0.428	/	( ( 1.614	+	1.586 )	/	2 )
=	0.428	/	1.6
=	26.75 %

where Working Capital is:

	Working Capital		(Q: Mar. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0.175	+	0.058)	-	(0.884	+	0	+	0.212)
=	-0.863

	Working Capital		(Q: Jun. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0.175	+	0.058)	-	(0.944	+	0	+	0.084)
=	-0.795

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Jun. 2023) EBIT data.

3. Operating Income is also linked to Operating Margin %:

Rapid Therapeutic Science Laboratories's Operating Margin % for the quarter that ended in Jun. 2023 is calculated as:

Operating Margin %	=	Operating Income (Q: Jun. 2023 )	/	Revenue (Q: Jun. 2023 )
	=	-0.104	/	0
	=	%

4. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Operating Income growth rate using Operating Income per share data.

Be Aware

Compared with a company's EBITDA margin, Operating Margin can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin may decline. Often the Operating Margin declines well before the company's revenue or even profit decline. Therefore, Operating Margin is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia's Operating Margin had already been in decline since 2002, although its earnings per share were still rising. Investors who paid attention to Operating Margin would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.

Rapid Therapeutic Science Laboratories Operating Income Related Terms

Thank you for viewing the detailed overview of Rapid Therapeutic Science Laboratories's Operating Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Rapid Therapeutic Science Laboratories (Rapid Therapeutic Science Laboratories) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Rapid Therapeutic Science Laboratories Inc (OTCPK:RTSL) » Definitions » Operating Income

Comparable Companies

Traded in Other Exchanges

N/A

Address

5580 Peterson Lane, Suite 120, Dallas, TX, USA, 75201

Website

https://www.rtslco.com

Rapid Therapeutic Science Laboratories Inc is a biotech company specializing in natural-based relief through aerosol delivery of cannabinoids to the systemic bloodstream through the pulmonary route of administration. The company manufactures its own branded metered dose inhalers (MDI) under the nhaler name using proprietary blends of pure cannabinoids such as cannabidiol (CBD) and cannabigerol (CBG). In addition, the company manufactures other aerosol devices for the delivery of cannabinoids other than MDI such as sublingual sprays.

Executives

Henry Anthony Punzi	director	1932 WALNUT PLAZA, CARROLLTON TX 75006
Scott Suggs Justin	director	639 SWORD BRIDGE DR., LEWISVILLE TX 75056
Sean Paul Berrier	10 percent owner	7108 DUFFIELD DR., DALLAS TX 75248
Schmidt Donal Ray Jr.	director, 10 percent owner, officer: President and CEO	5580 PETERSON LANE, SUITE 200, DALLAS TX 75240
Ryan Casey Johnson	director, officer: Chief Operating Officer	2307 CASTLE ROCK RD, CARROLTON TX 75007
Texas Mdi, Inc.	10 percent owner	5580 PETERSON LANE, SUITE 200, DALLAS TX 75240
D Hughes Watler	director, officer: CFO	2323 S. VOSS ROAD, STE. 510-12, HOUSTON TX 77057
Steve Bond	director, officer: CFO	28839 PUJOL ST., #832, TEMECULA CA 92590
Brent Willson	director, officer: CEO and President	5271 CAMINITO EXQUISITO, SAN DIEGO CA 92130